Myoderm biosimilar market intelligence reports: Avastin

January 14, 2013 6:41 AM

Myoderm, is a leader in the sourcing, distribution, and management of pharmaceutical products and supplies for pharmaceutical and biotech companies, CROs, clinical trial packagers, and other institutions.

The company is sourcing innovator products for biosmilar trials also and recently, they began to issue market intelligence reports for some originator products. The first report was about Avastin, the blockbuster of Roche/Genentech which is used in major types of cancer treatment.

Genentech has restrictions on this product and it is not available through traditional wholesale pharmacy channels. The manufacturer has to approve a pharmacy before they can purchase the product for patients. Unless deals are struck with specialty wholesalers or oncology pharmacies, the product is very hard to acquire on the secondary market.

Genentech will consider supplying the product for biosimilar trials, and has supported trials previously. They will want to know the name of the sponsor and some general trial/protocol information. They will not supply product if it’s being shipped outside of the US.

Shelf life, documentation and pricing information of Genentech are also included in the report.

Product is available in many local EU markets through Roche authorized distributors. In some markets, like UK and France, the product is a hospital-only line and not available on the wholesale level.

Roche will consider supplying the product for biosimilar trials, and has supported trials previously. They will want to know the EUDRACT number and list of countries for the study. They will not supply product if it’s being used in the US or Japan.

Again shelf life, documentation and pricing information of Avastin in Europe are detailed in the report.

If you want to get more details, you can check the report from here.


Source: Myoderm

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)

Latest News on Biosimilar News

Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?


Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!